Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nine key insights from over 760 interviews for ViiV Healthcare’s “Here as I Am” report.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
The Centers for Disease Control and Prevention estimates that about 36,400 people contracted HIV in 2018.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
We all need social support. That’s why this year’s NBHAAD theme is “We’re in This Together.”
Opioid use disorder is fueling a rise in youth hepatitis C cases and a stabilization of a long decline in HIV among people who use drugs.
The program’s home will be Callen-Lorde’s in-the-works site in downtown Brooklyn.
Foreign-born Latino men who have sex with men apparently have a lower rate of sex protected by PrEP, condoms or both.
The 2019 theme is: “Living with HIV or not…we’re fighting this together.”
Ask Hep answers a question about the risk of transmitting hepatitis C sexually.
Researchers provided an initial Truvada prescription to eligible gay and bi men and trans women at their first appointment.
Researchers analyzed data from 42 HIV centers in 11 Latin American nations.
U=U is 100% effective, and PrEP reduces the risk of getting HIV by 99% in men who have sex with men, according to new federal data.
The Milwaukee campaign aims to reduce HIV rates among people of color.
The CDC estimates that 40 percent of the 1.1 million people with HIV are undiagnosed or not receiving medical care for the virus.
Highlighting four tools to end HIV
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.